Loading
TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network. Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signalling between antigen presenting cells and lymphocytes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.92, animal model 0.27, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network.
No product in this corpus aims at TNFRSF14 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TNFRSF14: RNA low tissue specificity; high antibody staining in 11 normal tissues; highest cancer staining lymphoma (6 of 10 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Lung cancer (all types), Skin cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q92956; CIViC gene TNFRSF14; IntOGen TNFRSF14; Human Protein Atlas TNFRSF14 tissue; Open Targets ENSG00000157873 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Montgomery R.I. et al, Cell, 1996, "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family". Source.
Sources: HGNC HGNC:11912 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92956 (protein name, function text, keywords and locations (REST API)); CIViC gene TNFRSF14 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000157873 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.68, skin cancer 0.51, lung cancer 0.52 (GraphQL API, CC0)); IntOGen TNFRSF14 (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network. Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signalling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions. Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumour immune response. In the context of bacterial infection, acts as a signalling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines. Location: Cell membrane (UniProt). Locus 1p36.32 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Breast, Bronchus, Cervix, Colon, Duodenum, Endometrium, Liver, Lung.
Medium only: carcinoid, liver cancer, lung cancer, ovarian cancer.
HPA TNFRSF14 tissue · HPA TNFRSF14 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TNFRSF14" OR ABSTRACT:"TNFRSF14" OR TITLE:"TNF receptor superfamily member 14" OR ABSTRACT:"TNF receptor superfamily member 14" OR TITLE:"Tumor necrosis factor receptor superfamily member 14" OR ABSTRACT:"Tumor necrosis factor receptor superfamily member 14" OR TITLE:"TR2" OR ABSTRACT:"TR2" OR TITLE:"LIGHTR" OR ABSTRACT:"LIGHTR" OR TITLE:"CD270" OR ABSTRACT:"CD270") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNFRSF14, not a curated reading list.
Shares Checkpoint (two meanings), IntOGen, Non-Hodgkin lymphoma (all types).
Shares Checkpoint (two meanings), CIViC, IntOGen, Open Targets Platform.
Shares Checkpoint (two meanings), CIViC, IntOGen, Lung cancer (all types).
Shares Checkpoint (two meanings), Skin cancer (all types), CIViC, IntOGen.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.